Phrontline Biopharma is actively looking for partnership for project TJ101 and TJ102, which can bring synergy to maximize the value of these projects. TJ101 is an EGFR bispecific ADC (with topo i1 as payload) that targets a variety of indications including NSCLC, ESCC, HNSCC, Colon cancers etc. TJ102 is a Fra bispecific dual payload ADC that targets Fra low expression ovarian cancer, RCC etc. Our dual payload platform (topo 1i and microtubule inhibitor) has the advantages of increasing response and delaying drug resistance. Please contact info@phrotnline.com.cn for more detail information.